Risk for New Primaries Higher in Stage III/IV Melanoma

Share this content:
  • Melanoma on the Eyelid
  • Melanoma of the Foot (Early Stage)
  • Melanoma of the Foot (Late Stage)
  • Melanoma in the Loin
  • Melanoma on the Arm
  • Melanoma Skin Cells
  • Melanoma of the Neck
SLIDESHOW:

Melanoma

Risk for New Primaries Higher in Stage III/IV Melanoma
Risk for New Primaries Higher in Stage III/IV Melanoma

(HealthDay News) — Patients with stage III or IV melanoma who have not received treatment with BRAF inhibitors remain at risk for developing new primary melanomas (NPMs), although the incidence rates are lower than those observed in studies of dabrafenib and vemurafenib, according to research published online Dec. 2 in the Journal of Clinical Oncology.

RELATED: Targeting BRAF Mutation in Melanoma Treatment

Lisa Zimmer, MD, of the University Duisburg-Essen in Germany, and colleagues followed a large cohort of patients with stage III or IV melanoma, who were not treated with a BRAF inhibitor, to assess the background incidence of spontaneous NPMs.

The researchers found that the cumulative incidence rate of NPMs after diagnosis of stage III melanoma was 1.2% (95% confidence interval [CI], 0.86% to 1.51%) at 6 months, 1.8% (95% CI, 1.44% to 2.26%) at 1 year, and 5.9% (95% CI, 5.08% to 6.74%) at 10 years. 

The cumulative incidence rate of NPMs after diagnosis of stage IV melanoma was 0.2% (95% CI, 0.07% to 0.36%) at 3 months, 0.3% (95% CI, 0.15% to 0.51%) at 6 months, and 0.4% (95% CI, 0.25% to 0.7%) at 1 year. A higher incidence of NPMs was observed in patients with stage III/IV melanoma who were male or who had a history of multiple primary melanomas.

RELATED: Skin Cancer Resource Center

"Patients with stage III and stage IV melanoma remain at risk for development of further primary melanomas, particularly if they have a history of multiple primary melanomas before stage III or IV disease," the researchers wrote. "Although the incidence rates are lower than those observed in the studies of dabrafenib and vemurafenib, the results must be compared with caution because of the more frequent and thorough dermatologic assessments in the BRAF inhibitor studies."

Several researchers disclosed financial ties to pharmaceutical companies, including manufacturers of BRAF inhibitors.

References

  1. Zimmer L, Haydu LE, Menzies Am, et al. Incidence of New Primary Melanomas After Diagnosis of Stage III and IV Melanoma. J Clin Oncol. 2013;doi:10.1200/JCO.2013.49.5572.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs